OnlineBusinessBureau.com
We are not the Better Business Bureau. We're better!
 
   About Us
   Our Ratings
   Look up a Company
   File a Complaint
   Complaint Resolution
     Center
   Resources
   Membership - Join Now!
   Member Login
   Testimonials
   Contact Us

1,847,257 companies
in our database.

Join our weekly
Consumer Fraud
Alert Newsletter



Our members proudly
display this seal!

News Releases

Back

AlgiPharma AS - Product Pipeline Review - 2014 - New Market Research Report

Global Markets Direct's, 'AlgiPharma AS - Product Pipeline Review - 2014', provides an overview of the AlgiPharma AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AlgiPharma AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Full Report Details at
 - http://www.fastmr.com/prod/879204_algipharma_as_product_pipeline_review_2014.aspx?afid=101

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

 * The report provides brief overview of AlgiPharma AS including business description, key information and facts, and its locations and subsidiaries
 * The report reviews current pipeline of AlgiPharma AS's human therapeutic division and enlists all their major and minor projects
 * The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 * Special feature on out-licensed and partnered product portfolio
 * The report summarizes all the dormant and discontinued pipeline projects
 * Latest company statement
 * Latest news and deals relating to the AlgiPharma AS's pipeline products

Reasons to Get this Report

 * Evaluate AlgiPharma AS's strategic position with total access to detailed information on its product pipeline
 * Assess the growth potential of AlgiPharma AS in its therapy areas of focus
 * Identify new drug targets and therapeutic classes in the AlgiPharma AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 * Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 * Develop strategic initiatives by understanding the focus areas of AlgiPharma AS and exploit collaboration and partnership opportunities
 * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 * Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlgiPharma AS
 * Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 * Explore the dormant and discontinued projects of AlgiPharma AS and identify potential opportunities in those areas
 * Avoid Intellectual Property Rights related issues

Report Table of Contents:

AlgiPharma AS Snapshot
AlgiPharma AS Overview
Key Information
Key Facts
AlgiPharma AS - Research and Development Overview
Key Therapeutic Areas
AlgiPharma AS - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
AlgiPharma AS - Pipeline Products Glance
AlgiPharma AS - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
AlgiPharma AS - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
AlgiPharma AS - Drug Profiles
Oligomer G for Cystic Fibrosis
Product Description
Mechanism of Action
R&D Progress
Oligomer G for Bacterial Infectious
Product Description
Mechanism of Action
R&D Progress
Oligomer G for COPD
Product Description
Mechanism of Action
R&D Progress
Oligomer G for Wounds And Burns
Product Description
Mechanism of Action
R&D Progress
AlgiPharma AS - Pipeline Analysis
AlgiPharma AS - Pipeline Products by Route of Administration
AlgiPharma AS - Pipeline Products by Molecule Type
AlgiPharma AS - Recent Pipeline Updates
AlgiPharma AS - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
AlgiPharma AS, Key Information
AlgiPharma AS, Key Facts
AlgiPharma AS - Pipeline by Indication, 2014
AlgiPharma AS - Pipeline by Stage of Development, 2014
AlgiPharma AS - Monotherapy Products in Pipeline, 2014
AlgiPharma AS - Phase II, 2014
AlgiPharma AS - Preclinical, 2014
AlgiPharma AS - Discovery, 2014
AlgiPharma AS - Pipeline by Route of Administration, 2014
AlgiPharma AS - Pipeline by Molecule Type, 2014
AlgiPharma AS - Recent Pipeline Updates, 2014

List of Figures
AlgiPharma AS - Pipeline by Top 10 Indication, 2014
AlgiPharma AS - Pipeline by Stage of Development, 2014
AlgiPharma AS - Monotherapy Products in Pipeline, 2014
AlgiPharma AS - Pipeline by Top 10 Molecule Type, 2014

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available.  Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

 


Credit Secrets Bible

Get Paid for
Doing Surveys





The Online Business Bureau -- 21441 Pacific Boulevard -- Suite 200 -- Sterling, VA 20166 -- 202-558-5282
News Releases |  News Articles |  Financial Calculators |  Contact Us |  Privacy Policy | Terms of Use & Legal Notice
Copyright © 2018 Online Business Bureau, L. C.. All Rights Reserved.
We are not affiliated with the Council of Better Business Bureaus, Inc.